| MDL | MFCD00865733 |
|---|---|
| Molecular Weight | 420.85 |
| Molecular Formula | C19H21ClN4O5 |
| SMILES | ClC(C=C1)=CC=C1OC(C)(C)C(OCCN2C3=C(N(C(N(C)C3=O)=O)C)N=C2)=O |
Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2 [1] .
Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time) and has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 52 mg/mL ( 123.56 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3761 mL | 11.8807 mL | 23.7614 mL |
| 5 mM | 0.4752 mL | 2.3761 mL | 4.7523 mL |
| 10 mM | 0.2376 mL | 1.1881 mL | 2.3761 mL |